Literature DB >> 33672006

Curcumin Encapsulated in Crosslinked Cyclodextrin Nanoparticles Enables Immediate Inhibition of Cell Growth and Efficient Killing of Cancer Cells.

Karin Möller1, Beth Macaulay1, Thomas Bein1.   

Abstract

The efficiency of anti-cancer drugs is commonly determined by endpoint assays after extended incubation times, often after days. Here we demonstrate that curcumin encapsulated in crosslinked cyclodextrin nanoparticles (CD-NP) acts extremely rapidly on cell metabolism resulting in an immediate and complete inhibition of cell growth and in efficient cancer-cell killing only few hours after incubation. This early onset of anti-cancer action was discovered by live-cell high-throughput fluorescence microscopy using an environmental stage. To date, only very few examples of covalently crosslinked nanoscale CD-based (CD-NP) drug carriers exist. Crosslinking cyclodextrins enables the adsorption of unusually high payloads of hydrophobic curcumin (762 µg CC/mg CD-NP) reflecting a molar ratio of 2.3:1 curcumin to cyclodextrin. We have investigated the effect of CD-NP encapsulated curcumin (CD-CC-NP) in comparison to free, DMSO-derived curcumin nanoparticles (CC-NP) on 4 different cell lines. Very short incubations times as low as 1 h were applied and cell responses after medium change were subsequently followed over two days. We show that cell proliferation is inhibited nearly immediately in all cell lines and that a cell- and concentration dependent cancer-cell killing occurs. Anti-cancer effects were similar with free and encapsulated curcumin, however, encapsulation in CD-NP drastically extends the long-term photostability and anti-cancer activity of curcumin. Curcumin-sensitivity is highest in HeLa cells reaching up to 90% cell death under these conditions. Sensitivity decreased from HeLa to T24 to MDA MB-231 cells. Strikingly, the immortalized non-cancerous cell line MCF-10A was robust against curcumin concentrations that were highly toxic to the other cell lines. Our results underline the potential of curcumin as gentle and yet effective natural anti-cancer agent when delivered solvent-free in stabilizing and biocompatible drug carriers such as CD-NP that enable efficient cellular delivery.

Entities:  

Keywords:  IC50; anti-cancer; crosslinked cyclodextrin nanoparticles; curcumin; drug delivery; kinetic response profiles; label-free imaging

Year:  2021        PMID: 33672006     DOI: 10.3390/nano11020489

Source DB:  PubMed          Journal:  Nanomaterials (Basel)        ISSN: 2079-4991            Impact factor:   5.076


  5 in total

1.  Evaluation and Characterization of Curcumin-β-Cyclodextrin and Cyclodextrin-Based Nanosponge Inclusion Complexation.

Authors:  Hadeia Mashaqbeh; Rana Obaidat; Nizar Al-Shar'i
Journal:  Polymers (Basel)       Date:  2021-11-24       Impact factor: 4.329

Review 2.  Cyclodextrin-Based Nanosponges: Overview and Opportunities.

Authors:  Gianluca Utzeri; Pedro M C Matias; Dina Murtinho; Artur J M Valente
Journal:  Front Chem       Date:  2022-03-24       Impact factor: 5.221

3.  Nanoparticles for Bio-Medical Applications.

Authors:  Miguel Gisbert-Garzarán; María Vallet-Regí
Journal:  Nanomaterials (Basel)       Date:  2022-04-02       Impact factor: 5.076

4.  Curcumin Encapsulated into Biocompatible Co-Polymer PLGA Nanoparticle Enhanced Anti-Gastric Cancer and Anti-Helicobacter Pylori Effect.

Authors:  Jawed Alam; Fahima Dilnawaz; Sanjeeb Kumar Sahoo; Durg Vijai Singh; Asish Kumar Mukhopadhyay; Tahziba Hussain; Sanghamitra Pati
Journal:  Asian Pac J Cancer Prev       Date:  2022-01-01

5.  Combined Curcumin and Luteolin Synergistically Inhibit Colon Cancer Associated with Notch1 and TGF-β Signaling Pathways in Cultured Cells and Xenograft Mice.

Authors:  Rukayat Aromokeye; Hongwei Si
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.